December 26, 2014 10:30 PM ET

Biotechnology

Company Overview of Ra Pharmaceuticals, Inc.

Company Overview

Ra Pharmaceuticals, Inc. operates as an early-stage biotechnology company that develops peptides as novel therapeutics. The company offers drugs for intracellular protein-protein interactions and other unmet medical needs. Its drugs are used in the treatment of cancer, inflammation and autoimmune, diabetes, cardiovascular, and ophthalmology diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.

One Kendall Square

Building 1400 West

3rd Floor

Cambridge, MA 02139

United States

Founded in 2008

Phone:

617-401-4060

Fax:

617-401-4061

Key Executives for Ra Pharmaceuticals, Inc.

Co-Founder
Age: 56
Co-Founder and Chairman
Age: 46
Senior Director of Operations
Chief Business Officer
Vice President of Chemistry
Compensation as of Fiscal Year 2014.

Ra Pharmaceuticals, Inc. Key Developments

Ra Pharmaceuticals Appoints Pamela Esposito as Chief Business Officer

Ra Pharmaceuticals announced it has appointed Pamela Esposito, Ph.D., as Chief Business Officer to lead strategic and corporate development efforts for the Company. Dr. Esposito was most recently Senior Vice President, Strategic Planning & Business Development at Angiochem Inc., where she was instrumental in executing several important collaborations for the company. Prior to Angiochem, Pamela was Vice President of Business Development at Biovex, a clinical stage oncology company focused on melanoma.

Ra Pharmaceuticals, Inc. Announces Broad Collaboration with Merck & Co. Inc. to Develop Cyclomimetics

Ra Pharmaceuticals, Inc. announced that it has entered into a collaboration with Merck & Co. Inc. focused on the development of Cyclomimetics, a new class of compounds that have the diversity and specificity of antibodies while retaining the attributes of small molecules. Under the agreement, Ra Pharmaceuticals will use its proprietary Extreme Diversity platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas. Under the terms of the agreement, Ra Pharmaceuticals is eligible to receive up to $200 million in payments, including up-front and research funding, as well as upon the achievement of discovery, development, regulatory and commercialization milestones for multiple targets.

Similar Private Companies By Industry

Company Name Region
Global Grain Security, LLC United States
Berkeley Bioengineering Co. United States
Vet Therapeutics, Inc. United States
BioMarin/Genzyme LLC United States
ImmunoBiosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ra Pharmaceuticals, Inc., please visit www.rapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.